Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Demand Supply of Generics with Full Strengths
January 30, 2006
- Salaries Rose 1.7% in Healthcare & Welfare Sector in 2005: Korosho
January 30, 2006
- BUSINESS NEWS IN BRIEF
January 30, 2006
- R&D NEWS IN BRIEF
January 30, 2006
- Toyobo to Place Priority on Specialty Business Including Life Science
January 30, 2006
- JPMA Approves FY2006 Action Plan
January 23, 2006
- Review Process Will Be Speeded Up in 2nd Half of FY2006: PMDA Director Miyajima
January 23, 2006
- SEMINAR
January 23, 2006
- Mr Matsutani of HPB Supports Revised Prescription Form
January 23, 2006
- Eligibility Criteria for DPC Approved: Chuikyo
January 23, 2006
- Korosho Proposes Addition, Not Replacement of Prescription Form
January 23, 2006
- 200 More Hospitals Expected to Participate in DPC
January 23, 2006
- BUSINESS NEWS IN BRIEF
January 23, 2006
- Korosho to Eliminate Med. Institutions for Nursing Care
January 23, 2006
- New Union Opposes Banyu's Restructuring Plan
January 23, 2006
- Premiums Based on % of Referred Patients to Be Abolished
January 23, 2006
- JGPMA Wants to Talk More Freely with JPMA: Mr Yoshida
January 23, 2006
- NPhA Wants to See Single Basic Dispensing Fee
January 23, 2006
- Toho Stocks Generics of Sawai, Nichi-iko, and Kyowa Pharm.
January 23, 2006
- JPA Prefers Sweeping but Shallow Revision of Dispensing Fees
January 23, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…